Skip to main content
    A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.45
    -0.03 (-5.40%)

    Market Cap: $131.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Akebia Ther (AKBA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Akebia Ther reported revenue of $236.20M for the fiscal year ended Dec 31, 2025, up 47.5% from the year before. That year, net income was -$5.34M with a net margin of -2.3%, operating cash flow was $67.99M and free cash flow was $67.70M. The quarter ended Sep 30, 2026 had revenue of $36.90M and net income of -$14.35M.

    Revenue and Margins

    The operating margin was 9.9% in the fiscal year ended Dec 2025, the highest of the 7 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $1.53M, a compound annual rate of 75.1%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$236.20M+47.5%83.3%9.9%-2.3%
    Dec 2024$160.18M-17.7%60.6%-31.5%-43.3%
    Dec 2023$194.62M-33.5%61.9%-23.8%-26.7%
    Dec 2022$292.48M+38.2%70.7%-27.6%-32.2%
    Dec 2021$211.65M-28.2%28.8%-125.0%-133.3%
    Dec 2020$294.64M-12.0%-0.6%-128.2%-130.6%
    Dec 2019$335.00M+61.3%56.6%-85.5%-83.5%
    Dec 2018$207.74M+14.6%96.3%-85.8%-69.1%
    Dec 2017$181.23M+11706.3%100.0%-42.3%-40.7%
    Dec 2016$1.53MN/A100.0%-8889.9%-8843.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$236.20M$160.18M$194.62M$292.48M$211.65M$294.64M$335.00M$207.74M$181.23M$1.53M
    Cost of revenue$39.46M$63.18M$74.15M$85.57M$150.67M$296.48M$145.34M$7.77M$0$0
    Gross profit$196.73M$97.00M$120.47M$206.92M$60.98M-$1.83M$189.66M$199.97M$181.23M$1.53M
    Research and development$62.36M$37.65M$63.08M$129.99M$147.85M$218.49M$322.97M$291.01M$230.89M$115.78M
    Operating income$23.50M-$50.47M-$46.26M-$80.78M-$264.50M-$377.83M-$286.29M-$178.16M-$76.67M-$136.46M
    Net income-$5.34M-$69.41M-$51.92M-$94.23M-$282.02M-$384.84M-$279.66M-$143.59M-$73.67M-$135.75M
    EBITDAN/A-$13.20M-$8.27M-$40.23M-$224.13M-$341.32M-$249.25M-$176.89M-$75.24M-$135.86M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$36.90M$49.13M$53.54M$57.62M$58.77M$62.47M$57.34M$46.50M$37.43M$43.65M$32.61M$56.20M
    Gross profit$30.54M$38.70M$41.25M$45.09M$49.38M$52.55M$49.71M$26.13M$23.27M$26.60M$21.00M$37.53M
    Operating income-$11.46M-$6.33M-$4.70M-$8.55M$4.45M$14.09M$13.51M-$14.31M-$12.51M-$8.72M-$14.94M$1.37M
    Net income-$14.35M-$8.91M-$9.05M-$12.24M$540.00K$247.00K$6.11M-$22.80M-$20.04M-$8.58M-$17.98M$612.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $48.25M by $136.59M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$376.56M$220.67M$241.70M$356.05M$529.35M$644.14M$771.20M$996.54M$364.25M$300.22M
    Current assets$252.96M$113.83M$118.15M$185.18M$271.15M$371.44M$309.53M$468.27M$358.36M$296.32M
    Cash and equivalents$184.84M$51.87M$42.92M$90.47M$149.80M$228.70M$147.45M$104.64M$70.16M$187.34M
    Total liabilities$343.95M$269.86M$272.29M$350.82M$455.34M$396.52M$376.44M$360.61M$241.67M$232.10M
    Short-term debt$0$9.71M$17.50M$32.00M$97.54M$0$4.99M$15.00M$0$9.00K
    Long-term debt$48.25M$38.69M$17.18M$34.08M$0$96.38M$75.81MN/A$0$5.00K
    Shareholder equity$32.61M-$49.19M-$30.58M$5.23M$74.01M$247.62M$394.76M$635.93M$122.57M$68.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$342.13M$349.66M$362.52M$376.56M$364.15M$345.60M$310.19M$220.67M$207.14M$220.20M$225.48M$241.70M
    Total liabilities$321.76M$324.64M$335.14M$343.95M$322.56M$316.37M$285.60M$269.86M$257.54M$253.95M$252.74M$272.29M
    Cash and equivalents$159.25M$155.55M$162.64M$184.84M$166.44M$137.31M$113.37M$51.87M$34.02M$39.50M$41.96M$42.92M
    Shareholder equity$20.37M$25.02M$27.38M$32.61M$41.59M$29.22M$24.58M-$49.19M-$50.40M-$33.75M-$27.26M-$30.58M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 99.6% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$67.99M-$40.66M-$23.38M-$73.15M-$252.97M-$110.39M-$257.44M-$97.49M-$56.16M$57.91M
    Capital expenditures$291.00K$33.00K$0$114.00K$59.00K$317.00K$6.66M$1.61M$1.62M$2.66M
    Free cash flow$67.70M-$40.69M-$23.38M-$73.27M-$253.02M-$110.70M-$264.10M-$99.10M-$57.78M$55.24M
    Investing cash flow-$7.93M-$33.00K$0-$114.00K$39.94M-$40.00M$211.18M$36.59M-$177.26M$12.71M
    Financing cash flow$72.93M$49.66M-$25.21M$14.60M$133.73M$231.72M$88.97M$96.56M$116.24M$66.95M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$2.33M$3.52M-$21.21M$31.13M$28.11M$22.34M-$13.59M-$4.47M-$6.70M-$10.07M-$19.43M-$2.31M
    Capital expenditures$706.00K$1.08M$62.00K$70.00K$77.00K$126.00K$18.00K$2.00K$2.00K$29.00K$0$0
    Free cash flow$1.63M$2.45M-$21.27M$31.06M$28.03M$22.22M-$13.61M-$4.47M-$6.70M-$10.10M-$19.43M-$2.31M
    Last 12 quarters

    Frequently Asked Questions About AKBA

    What is Akebia Ther's annual revenue?

    Akebia Ther reported revenue of $236.20M for the fiscal year ended Dec 31, 2025.

    How fast is Akebia Ther's revenue growing?

    Revenue was up 47.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -6.9%.

    Is Akebia Ther profitable?

    No. Akebia Ther reported net income of -$5.34M for the fiscal year ended Dec 31, 2025, with a net margin of -2.3%.

    How much free cash flow does AKBA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $67.99M minus capital expenditures of $291.00K produced free cash flow of $67.70M.

    How much debt does Akebia Ther have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $48.25M, short-term debt of $0 and cash and equivalents of $184.84M.